brca
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Opinion: No, FDA Didn’t Really Approve 23andMe’s <em>BRCA</em> Test
Opinion: No, FDA Didn’t Really Approve 23andMe’s BRCA Test
Cecile Janssens | Mar 19, 2018
Rather, the breast cancer mutation screen was classified as a type of medical device with obligations for the company to reduce risks to customers.
First Direct-to-Consumer BRCA Test Authorized by FDA
First Direct-to-Consumer BRCA Test Authorized by FDA
Kerry Grens | Mar 6, 2018
The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.